Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the third quarter of 2023.
September quarter revenues rose 15% year-over-year to $3.36 billion. Net product sales, which account for more than 50% of total revenues, edged down by 1%.
Adjusted earnings moved up 4% to $11.59 per share in Q3 from $11.14 per share in the same period of 2022. Unadjusted profit was $1.0 billion or $8.89 per share, compared to $1.32 billion or $11.66 per share last year.
“We have continued our momentum in the third quarter of 2023 with double-digit year-over-year revenue growth, driven by strong Dupixent and Libtayo performance, as well as strong initial uptake of EYLEA HD following its late August launch,” said the company’s CEO Leonard Schleifer.
CVS Health Corporation (NYSE: CVS) reported record full-year 2025 consolidated revenues of $402.1 billion, a…
Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues…
The industrial materials manufacturer reported flat fourth-quarter sales and a full-year organic growth rate of…
Overview Harley-Davidson, Inc. reported consolidated fourth-quarter 2025 results that point to continued pressure on profitability…
The Coca-Cola Company (NYSE: KO) reported its fourth quarter 2025 earnings results today. Net revenues…
The South Korean telecommunications provider reported a significant increase in annual profit for 2025, supported…